临床心脏病管理计划:通过与初级保健和专家 (CHAMP-HF) 合作,改变实践
Marianne Parent1,2, Jacinthe Leclerc3,4, Eileen O'Meara1,2
1Faculty of Medicine, University of Montreal, Montreal, Canada.
International journal of cardiology. Heart & vasculature
|February 1, 2024
概括
从专家那里接受心力衰竭 (HF) 教育的初级保健提供者 (PCP) 改善了心力衰竭与减少喷射率 (HFrEF) 的早期诊断和指导方针导向医学治疗 (GDMT). 这种合作也促进了PCP对管理HF的信心.
科学领域:
- 心脏病学 心脏病学
- 初级医疗保健医学 一级医疗保健医学
- 医疗教育 医学教育
背景情况:
- 在住院患者中,心力衰竭 (HF) 往往是晚期诊断的,这表明需要早期社区检测.
- 目前在初级保健机构改善高频率意识和管理的策略需要进一步调查.
研究的目的:
- 评估HF专家和PCP之间的教育伙伴关系对HF诊断和管理的影响.
- 评估心力衰竭与减少喷射率 (HFrEF) 和PCP信心水平的指南导向医学治疗 (GDMT) 的变化.
主要方法:
- 从2019年3月到2020年6月,进行了一项具有前后设计的观察性研究.
- 高频专家每月为参与的PCP提供教育会议.
- 通过医疗病历审查,行政数据库和PCP问卷收集数据.
主要成果:
- 在教育干预后,HF诊断人数增加了28.6%.
- 对HFrEF患者实施GDMT显著改善,接受三重治疗的患者增加了一倍 (22.9%至45.7%,p=0.0047).
- 在干预后,PCP对高压管理的信心从16.7%增加到50%.
结论:
- 高频专家和PCP之间的协作教育方法提高了HF早期诊断和HFrEF的GDMT实施.
- 这种干预成功地增加了PCP对心力衰竭管理的信心,即使是在COVID-19大流行期间.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340


